William Dunn
Net worth: - $ as of 2026-07-30
Net worth: - $ as of 2026-07-30
William H.
Dunn is currently an Independent Director at Prothena Corp.
Plc since 2023.
Formerly, Dr. Dunn was Director-Neurology Products at the Center for Drug Evaluation & Research from 2005 to 2019 and Director-Neuroscience at the US Food & Drug Administration from 2019 to 2023.
Education includes an undergraduate degree from the University of Virginia and a doctorate from F Edward Hebert School of Medicine.
| Company | Date | Number of shares | Valuation | Valuation date |
|---|---|---|---|---|
PROTHENA CORP. PLC -.--% | 2026-05-14 | 0 ( -.--% ) | - $ | 2026-07-30 |
| Companies | Position | Start |
|---|---|---|
| PROTHENA CORPORATION PLC | Director/Board Member | 2023-05-15 |
| Companies | Position | End |
|---|---|---|
US Food & Drug Administration
US Food & Drug Administration General GovernmentGovernment Operates agencies to protect health and human services | Corporate Officer/Principal | 2023-01-31 |
Center for Drug Evaluation & Research
Center for Drug Evaluation & Research General GovernmentGovernment Operates agencies for the department of health and human services | Corporate Officer/Principal | 2018-12-31 |
Active
Inactive
Listed companies
Private companies
1st degree connections
1st degree companies
Male
Female
Members of the board
Executives
| Private companies | 4 |
|---|---|
University of Virginia
University of Virginia Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
US Food & Drug Administration
US Food & Drug Administration General GovernmentGovernment Operates agencies to protect health and human services | Government |
Center for Drug Evaluation & Research
Center for Drug Evaluation & Research General GovernmentGovernment Operates agencies for the department of health and human services | Government |
Prothena Corp. Plc
Prothena Corp. Plc BiotechnologyHealth Technology Focuses on the discovery and development of novel antibodies | Health Technology |
Select your edition
All financial news and data tailored to specific country editions